Explore the preclinical research catching our eye in September 2026, from siRNA and in vivo CRISPR to targeted protein ...

Take a look at the Eli Lilly pipeline in 2026 as the incretin franchise grows and fuels the rest of the company's pipeline.

Discover how early optimization in stable cell line development accelerates timelines and reduces downstream bottlenecks.

Discover Andy Brown's long and arduous journey battling a type of non-Hodgkin lymphoma and how a clinical trial altered his ...

The companies Moderna, Amylyx Pharmaceuticals, and Braveheart Bio bagged the biggest biotech funding rounds overall in August ...

Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and ...

See why investor confidence in cell and gene therapies now depends on execution and supply chain strategy—not strong science ...

Find out what came out of the ESC Congress 2026, from phase 3 successes and failures to earlier-stage programs.

The concept of targeted therapeutics is often traced back to German Nobel laureate Paul Ehrlich’s “magic bullet” in 1907, which envisioned a single entity that could both recognize a disease target ...

Home to excellent research institutions, a thriving life sciences community, a strong collaborative culture, and a strategic location at the heart of Europe, Ghent is now investing in cutting-edge ...

As U.S. budget cuts and freezes push healthcare and biopharma research in the States towards uncertainty, could Europe be the destination that science talent flocks towards? That’s what the European ...